Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis

Next Previous
X
Search
Trial Profile

A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms BE ABLE 2
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 12 Jun 2020 According to an UCB media release, data will be presented as part of a virtual session for the American Academy of Dermatology. (AAD) 2020 Annual Meeting.
    • 28 May 2020 Results published in the Journal of the American Academy of Dermatology.
    • 08 Nov 2019 Results published in the UCB Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top